AstraZeneca PLC — Board/Management Information 2023

Apr 26, 2023

National Storage Mechanism | Additional information

RNS Number : 5919X

AstraZeneca PLC

26 April 2023

26 April 2023 16:45 BST

Director Declaration

AstraZeneca PLC (the Company) today announced that Aradhana Sarin, Chief Financial Officer and Executive Director of the Company, has been appointed as an independent director of Anheuser-Busch InBev with effect from 26 April 2023, for a period of four years.

This announcement is made pursuant to Listing Rule 9.6.14 R (2).

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNEQLFLXZLXBBF